Vivesto AB
0N4A.L
London Stock Exchange0.08
SEK
+0.00
- -
Vivesto AB
0N4A.L
(London Stock Exchange)
Recent
price
0.08
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Vivesto AB (Nasdaq Stockholm: VIVE; ticker: 0N4A.L) develops and commercializes novel oncology therapeutics leveraging proprietary drug delivery platforms to enhance solubility, efficacy and safety profiles of active pharmaceutical ingredients for human and veterinary applications. The company's core products and pipeline include Apealea (paclitaxel micellar), approved in the European Union and select territories for first-relapse platinum-sensitive ovarian, peritoneal or fallopian tube cancer in combination with carboplatin; Cantrixil (TRX-E-002-1), a third-generation benzopyran tubulin inhibitor in development for hematological cancers including blood malignancies following positive preclinical efficacy data; Docetaxel micellar, a patented XR-17 formulation in Phase 1b for advanced prostate cancer; and the veterinary program Paccal Vet (paclitaxel micellar), undergoing pilot clinical evaluation in dogs with splenic hemangiosarcoma post-splenectomy and dose-finding studies in cats with solid tumors; complemented by Doxophos Vet (doxorubicin formulation) for canine lymphoma. Vivesto operates primarily from headquarters in Solna and Uppsala, Sweden, targeting global markets with a focus on regions including Europe and North America through partnerships such as Elevar Therapeutics for Apealea commercialization; founded in 1988 as Oasmia Pharmaceutical AB, which rebranded to Vivesto AB in March 2022. Recent developments encompass the March 2025 acquisition of full global rights to Cantrixil from Kazia Therapeutics for USD 1 million including all intellectual property to accelerate hematological cancer programs amid promising combination therapy preclinical results and new patent filings; a fully secured rights issue of approximately SEK 53.8 million resolved in November 2025 pending extraordinary general meeting approval to fund pipeline advancement; and ongoing manufacturing for Cantrixil clinical trials alongside positive 2024 preclinical data supporting blood cancer indications.